

**Insert electronic letterhead  
FOR IMMEDIATE RELEASE**

**Media Contact**

Catherine Haskins  
847-989-1194  
catherine@haskinsconsultinginc.com

**Basepaws Launches Exclusive New Genomic Screening Tools for Veterinary Teams**

Providing Insights for Personalized Patient Care

LOS ANGELES, CA., July 28, 2022 – Basepaws Inc., a Zoetis company (NYSE: ZTS) and pioneer in pet care genetics, today launches a comprehensive portfolio exclusively for veterinary professionals: genetic and oral microbiome screening tools for disease risk. Basepaws Veterinary genetic and oral microbiome tests give veterinary teams actionable screening tools with valuable insights to help identify health risks sooner and provide better health outcomes for all cats and dogs.

Basepaws is committed to providing veterinarians with genomic tests for clinical use that feature the latest technology. Basepaws' DNA sequencing provides more detailed and specific insights than the consumer-facing methods. Basepaws Veterinary genetic tests screen for 64 feline health markers and over 210 canine health markers associated with known genetic diseases. Basepaws Veterinary oral microbiome tests analyze more than 600 relevant oral microbes to assess risk for the most common feline dental disease. The information can guide veterinarians and pet parents in selecting annual wellness programs, routine diagnostic tests, and lifestyle changes based on an individual pet's genetics.

"Pet genetics is ushering in an era of truly personalized and proactive medicine," says Ernie Ward, DVM, Basepaws Veterinary Medical Lead. "Knowing a pet's genetic risk factors and oral microbiome can help eliminate many clinical blind spots and allow veterinarians to recommend targeted diagnostic monitoring and lifestyle interventions based on scientific evidence instead of generic, species- or breed-specific advice."

Basepaws also creates 'personalized proactive pet care' by allowing veterinarians and pet parents to better monitor for subtle signs of illness based on a pet's genetic risk profile, allowing for earlier interventions, potentially leading to better patient outcomes.

Basepaws is launching exclusively with MWI Animal Health, a leading distributor of animal health products and services and a subsidiary of AmerisourceBergen, to accelerate veterinarians' access to their portfolio of genomic and oral microbiome screening tools.

"Our veterinary launch with MWI is a big milestone for pet genetics," says Kristin Wuhrman, Basepaws EVP of Veterinary Strategy and Operations. "As the first pet genetics company to partner with one of North America's largest veterinary distributors, we are able to bring veterinarians actionable genomic screening tools, providing improved patient insights that enrich client bonds and practice success."

"The pace of innovation across the animal health industry continues to accelerate. At MWI, we continue to expand our services and enhance our distribution capabilities to ensure veterinarians nationwide have timely and reliable access to products that have the potential to help pets live longer and healthier lives," said Steve Shell, president of MWI Animal Health. "We are excited to work with Basepaws to provide veterinarians efficient access to the company's new screening tools."

Veterinary professionals interested in bringing pet genetics into their practice can visit <https://www.basepawsvet.com/>, email [vet@basepaws.com](mailto:vet@basepaws.com) or call 888-636-4691 to learn more.

**-MORE-**

#### **ABOUT BASEPAWS**

Basepaws, a leader in pet care genetics, provides pet genetic and microbiome testing, tools and resources exclusively for veterinarians. Basepaws is committed to companion animal health research and is currently studying a number of common diseases with a variety of institutions throughout North America. Founded in 2017 by Anna Skaya, the company is based in Los Angeles, California. For more information about our veterinary product, visit <https://www.basepawsvet.com/>.

#### **ABOUT ZOETIS**

As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After 70 years innovating ways to predict, prevent, detect and treat animal illness, Zoetis continues to stand by those raising and caring for animals worldwide – from livestock farmers to veterinarians and pet owners. The company's leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of \$7.8 billion in 2021 with approximately 12,100 employees. For more information, visit [www.zoetis.com](http://www.zoetis.com).

#### **ABOUT AMERISOURCEBERGEN**

AmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the development and delivery of pharmaceuticals and healthcare products. As a leading global healthcare company, with a foundation in pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency and reliability for human and animal health. Our 42,000 global team members power our purpose: We are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #10 on the Fortune 500 with more than \$200 billion in annual revenue. Learn more at [www.amerisourcebergen.com](http://www.amerisourcebergen.com).

**###**